Centralized pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey

Angiology

Volumn 61, Issue 5, 2010, Pages 465-474

  Elisaf, Moses S ^a   Nikas, Nikos ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ASTRAZENECA   (United Kingdom)

Author keywords

cardiovascular; coronary; Greece; guidelines; hypercholesterolemia; lipids; low density lipoprotein

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG USE; FEMALE; GREECE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; SECONDARY PREVENTION; SMOKING;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GREECE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY ASSURANCE, HEALTH CARE;

EID: 77954051563     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710366432     Document Type: Article

References (37)

1. British Heart Foundation. European Cardiovascular Disease Statistics. London, UK: British Heart Foundation; 2005.
2. British Heart Foundation. European Cardiovascular Disease Statistics. London, UK: British Heart Foundation; 2008.
3. WHO. European Health for All Database. 2008.
4. Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493). 1267-1278.
5. Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 (21). 2195-2207.
6. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352 (14). 1425-1435.
7. Rosenson RS Statins: can the new generation make an impression ? Expert Opinion Emerg Drugs. 2004; 9 (2). 269-279.
8. Graham I., Atar D., Borch-Johnsen K., Boysen G., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007; 14 (Suppl 2). E1-E40.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110 (2). 227-239.
10. Rydén L., Standl E., Bartnik M., et al. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J. 2007; 28 (1). 88-136.
11. Cannon C., Braunwald E., McCabe C., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350 (15). 1495-1504.
12. Maruthur NM, Wang NY, Appel LJ Lifestyle interventions reduce coronary heart disease risk. Results from the PREMIER trial. Circulation. 2009; 119 (15). 2026-2031.
13. Iglseder B., Moroder T., Staffen W., Ladurner G. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig. 2005; 25 (11). 709-717.
14. Diamantopoulos EJ, Athyros VG, Yfanti GK, et al. OLYMPIC Study Group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology. 2005; 56 (6). 731-741.
15. Malik S., Lopez V., Chen R., Wu W., Wong ND Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007; 77 (1). 126-133.
16. Klingman D., Williams SA, Benner JS, Smith TW, Ahn J., O'Donnell JC Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J. 2005; 150 (3). 595-601.
17. Kotseva K., Wood D., De Backer G., et al. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373 (9667). 929-940.
18. Pearson TA, Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160 (4). 459-467.
19. Waters DD, Brotons C., Chiang CW, et al. Lipid treatment assessment project 2. A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009; 120 (1). 28-34.
20. Lehane E., McCarthy G. Medication non-adherence-exploring the conceptual mire. Int J Nurs Pract. 2009; 15 (1). 25-31.
21. Liberopoulos EN, Florentin M., Mikhailidis DP, Elisaf MS Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008; 7 (6). 717-725.
22. Penning-van Beest FJ, Termorshuizen F., Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007; 28 (2). 154-159.
23. Simons LA, Levis G., Simons J. Apparent discontinuation rates in patients prescribed lipid lowering drugs. Med J Aust. 1996; 164 (4). 208-211.
24. Smith DA, Harnick D., Kilaru R. Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994 and 1999). Am J Cardiol. 2001; 88 (12). 1417-1419.
25. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005; 96 (4). 556-563.
26. Hatzitolios AI, Athyros VG, Karagiannis A., et al. IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol. 2009; 134 (3). 322-329.
27. Daskalopoulou SS, Doonan RJ, Mikhailidis DP Undertreatment of hypercholesterolemia. Curr Med Res Opin. 2010; 26 (2). 439-443.
28. Hermans MP, Castro Cabezas M., Strandberg T., et al. Centralised pan-European survey on the under-treatment of hypercholesterolemia in patients using lipid lowering drugs (CEPHEUS). Value Health. 2007; 10 (6). PCV68.
29. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med. 2005; 353 (5). 487-497.
30. Dunbar-Jacob J., Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM Adherence in chronic disease. Annu Rev Nurs Res. 2000; 18: 48-90.
31. McDonnell PJ, Jacobs MR Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36 (9). 1331-1336.
32. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health System Pharmacy. 2001; 58 (12). 1126-1132.
33. Brookhart MA, Patrick AR, Schneeweiss S., et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007; 167 (8). 847-852.
34. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997; 18 (11). 1718-1724.
35. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005; 25 (8). 1035-1043.
36. Rasmussen JN, Chong A., Alter DA Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297 (2). 177-186.
37. Chimonas T., Athyros VG, Ganotakis E., et al. Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology. 2010; 61 (1). 49-57.